Drug Approval ProspectsAnalysts see an 85% probability of FDA approval for reproxalap, aligning with the FDA resubmission approval rates for novel drugs.
Financial PositionThe company has approximately $101M in cash and expects the remaining costs for the ongoing trials to be only around $6M, which keeps the company in a favorable financial position.
Partnership OpportunitiesThe outstanding option agreement with AbbVie addresses possible development and commercialization of reproxalap in the US market, which is seen as an upside with option execution potentially before approval.